Allergies are on the rise globally, with epidemiological studies indicating that 1 in 5 individuals is affected by this condition. The relentless symptoms of allergies, such as persistent sneezing and rhinorrhea (runny nose), are highly disruptive, severely impairing sleep quality, workplace productivity, and overall quality of life.

Historically, the majority of conventional antiallergic medications were associated with significant sedation (drowsiness) and possessed a short duration of action, necessitating multiple daily doses to maintain symptom control around the clock.

Neotadin®: A Second-Generation Antihistamine

Leveraging over seven decades of pioneering excellence in quality and innovation, Dr. Abidi Pharmaceuticals introduced a novel antihistamine, Desloratadine, to physicians and allergy sufferers in late 2018 (Autumn 1397). Marketed under the brand name Neotadin®, this medication restores comfort and quality of life to allergic patients with just a single daily dose.

Neotadin® provides rapid relief from allergic symptoms. It is among the first antihistamines to eliminate the undesirable adverse effects of earlier generations, notably drowsiness, while delivering rapid-onset clinical efficacy.

Neotadin®: Now Available OTC

Given the unique clinical benefits of Neotadin® and the unparalleled trust it has garnered among healthcare professionals and patients alike, the Iran Food and Drug Administration (IFDA) officially reclassified Neotadin® to the Over-The-Counter (OTC) list in early 2020 (Winter 1398).

Consequently, individuals seeking relief from allergy symptoms can now conveniently access their preferred treatment simply by visiting a pharmacy. Neotadin® can be obtained without a physician’s prescription, following a brief consultation with a pharmacist. (For more detailed clinical information, please visit the Neotadin® product page.)

About Desloratadine

Desloratadine has received approval from the US Food and Drug Administration (FDA) for the following indications:

– Intermittent (seasonal) allergic rhinitis in children (from 2 years of age) and adults.

– Persistent allergic rhinitis in children (from 6 months of age) and adults.

– Chronic idiopathic urticaria (hives of unknown cause) in children (from 6 months of age) and adults.

Pharmacological Profile of Neotadin® (Generic: Desloratadine):

– Exhibits the lowest incidence of sedation (drowsiness) compared to other second-generation antihistamines.

– Clinical onset of action occurs in less than 1 hour post-administration, reaching peak clinical efficacy approximately 3 hours after ingestion.

– Possesses a prolonged half-life of 27 hours and undergoes hepato-renal excretion.

– Efficacy and absorption remain completely unaffected by the concurrent consumption of food or beverages.

About Allergies

An allergy is an abnormal hypersensitivity reaction of the immune system. In allergic individuals, the immune system overreacts to otherwise harmless environmental substances. These triggers—such as pollen, mold, and animal dander—are known as allergens. Allergies are highly prevalent, affecting 2 out of every 10 people. While most types of allergies are not completely curable, their severity and clinical impact can be significantly mitigated through targeted therapeutic strategies and management protocols.

Common Symptoms of Allergies Include:

– Watery or itchy eyes

– Sneezing or coughing

– Rhinorrhea (runny nose), nasal itching, and congestion

– Skin irritation and pruritus (itching)

– Fatigue or malaise

– Urticaria (hives)

 

IR-0721-NTD-5827-PR